Oxford’s Brainomix proves value of lung imaging biomarkers in new studies

Brainomix has presented a series of new studies at the American Thoracic Society (ATS) Conference in San Diego.

The Oxford firm just secured clearance from the US Food and Drug Administration (FDA) for its latest imaging product, the 360 e-Lung.

Dr Michalis Papadakis, CEO and co-founder of Brainomix, said: “The studies presented this week at ATS are a reflection of our continual focus on scientific excellence and academic collaboration with both world-class institutions as well as with life science partners.

“The results highlight the prognostic value of our novel Brainomix lung imaging biomarkers to accurately predict disease progression in Idiopathic Pulmonary Fibrosis (IPF) and non-IPF patients.”

Among the studies presented was a research collaboration with Heidelberg University in which a cohort of 347 patients with non-IPF over a 10-year period was analysed with Brainomix’s novel lung imaging biomarker.

The results, said Professor Dr Michael Kreuter from the Mainz Center for pulmonary diseases in Germany, showed the biomarker to be a ‘valuable predictor of progressive disease in this cohort’.

Brainomix also showcased research in partnership with Avalyn Pharma in Seattle and separately with AstraZeneca in Oxford.